Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate—Danish National Register Based Cohort Study
- 499 Downloads
In this Danish national register-based cohort study, we examined the effects of alendronate on the development of colon cancers and survival. The incidence of colon cancer and mortality rate, once colon cancer had been diagnosed, were lower in patients treated with alendronate, posing the question whether alendronate acts as chemopreventive.
When bisphosphonates are given by mouth, around 99% remains non-absorbed in the intestine. Based on their biochemical actions, we predicted that oral bisphosphonates might prevent colon cancers.
This is a Danish national register-based cohort study. We identified 30,606 women aged 50+, mean age 71.9 years, who had not previously taken treatments for osteoporosis, who began to take alendronate in 1996–2005, and assigned 124,424 individually age- and gender-matched control subjects. The main outcome measure was colorectal cancers incidence and post-diagnosis survival in patients taking oral alendronate for osteoporosis.
Cox proportional hazards analysis of death due to colon cancer showed lower risk in alendronate users, crude hazard ratio (HR) 0.69 (95% CI 0.59–0.81) with an adjusted HR of 0.62 (95% CI 0.52–0.72). The reduction in risk comprised both a lower incidence of colon cancer-adjusted HR 0.69 (95% CI 0.60–0.79) and a lower mortality once colon cancer had been diagnosed, adjusted HR 0.82 (95% CI 0.70–0.97). Weekly alendronate was associated with a greater risk reduction than daily alendronate. The main findings were unaffected by excluding patients from the analysis who had pulmonary disease, a major co-morbid condition in users of alendronate and an important cause of death.
The risk of overall deaths from cancer and in particular death caused by colon cancer was significantly and substantially decreased (40%) in patients treated with alendronate, with survival curves deviating progressively after 2 years. Also, the incidence of colon cancer was lower in those patients.
KeywordsColorectal cancer Incidence Mortality Oral bisphosphonates
Conflicts of interest
M. Pazianas: Grant/Research support from the Alliance for Better Bone Health and Warner Chilcott. B. Abrahamsen: Grant/Research support from Novartis, Nycomed, Amgen, Speakers Bureau with Merck, Eli Lilly. P. Eiken: Grant/Research support from Amgen, Speakers Bureau with Nycomed, Roche, Eli Lilly and Servier. R. Eastell: Grant/Research support from Amgen, Novartis, Procter & Gamble, Servier, Ono Pharmaceutical, GlaxoSmithKline, AstraZeneca. Speakers Bureau with Eli Lilly. R.G.G. Russell: Research support from Procter and Gamble, Sanofi-Aventis, and Warner Chilcott, Consultant/speaker and legal activities Amgen, GlaxoSmithKline, Roche, Procter and Gamble, Sanofi-Aventis, Novartis, Eli Lilly, Teva and Warner Chilcott.
- 9.Hosmer DW, Lemeshow S (1999) Applied survival analysis: regression modeling of time to event data, vol 6. Wiley, New YorkGoogle Scholar
- 21.(2010) Statins lose prevention ground. Nat Rev Cancer 10:385Google Scholar
- 33.Benzaid I, Clezardin P (2010) Nitrogen-containing bisphosphonates and human gammadelta T cells IBMS BoneKEy 7: 208-217. http://www.bonekey-ibms.org/cgi/content/full/ibmske
- 43.Abrahamsen B, Pazianas M, Eiken P, Russell RG, Eastell R (2011) Esophageal and gastric cancer incidence and mortality in alendronate users. J Bone Miner Res. doi: 10.1002/jbmr.1481 [Epub ahead of print]
- 45.Pazianas M, Russell RGG (2011) Potential therapeutic effects of oral bisphosphonates on the intestine. Ann N Y Acad Sci. [Epub ahead of print]Google Scholar